Endothelial RANK signaling triggers bone marrow inflammaging through IL-1β expression
This study identifies endothelial RANK signaling as a critical driver of bone marrow inflammaging by inducing IL-1β expression, which leads to senescent cell accumulation, hematopoietic stem cell dysfunction, and myeloid-biased hematopoiesis, thereby offering a potential therapeutic target for age-related diseases.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Aging is not merely the passage of time; it is a biological process where the body's tissues gradually lose their ability to repair and renew themselves. In the bone marrow, the spongy tissue inside our bones that produces blood cells, this decline manifests as a shift in how blood is made. Instead of producing a balanced mix of immune cells, the aging marrow begins to favor the production of certain types of white blood cells while suppressing others, a state known as myeloid-biased hematopoiesis. This shift is accompanied by a chronic, low-grade inflammation that researchers call inflammaging. This persistent inflammation damages the very stem cells needed to regenerate the body, creating a cycle that contributes to frailty and age-related diseases. For decades, scientists have known that old cells accumulate in these tissues and secrete harmful chemicals, but the specific trigger that starts this cascade in the bone marrow has remained a mystery.
A team of researchers has now identified a surprising starting point for this process: the blood vessels themselves. In a study published recently, scientists discovered that a specific signaling pathway within the endothelial cells, which line the interior of blood vessels, acts as a master switch for bone marrow aging. They found that as mice grow older, these blood vessel cells begin to receive a specific chemical signal that turns on a receptor called RANK. Once activated, this receptor prompts the blood vessel cells to produce a potent inflammatory molecule called IL-1β. This molecule then travels to nearby bone marrow stem cells, damaging them and forcing them into a state of permanent dormancy known as senescence. The accumulation of these dormant, inflammatory cells is what drives the shift in blood production and the overall decline of the marrow.
The investigation began by observing mice that lacked a natural brake on this signaling system. The researchers studied young mice that were genetically unable to produce a protein called osteoprotegerin, which normally blocks the RANK signal. Even though these mice were young, their bone marrow looked and behaved like that of much older animals. They were filled with senescent cells and showed the characteristic shift toward myeloid-biased blood production. This suggested that an overactive RANK signal could accelerate the aging process. To confirm that this signal was indeed the culprit, the scientists treated these young mice with an antibody that blocked the RANK signal. The treatment worked like a reset button: the mice stopped accumulating senescent cells, and their blood production returned to a healthy, balanced state. This proved that the RANK signal was not just a bystander but a direct driver of the aging phenotype.
To pinpoint exactly where this signal was happening, the researchers used a fluorescent tracer to follow the path of the RANK signal in the bone marrow of middle-aged mice. They discovered that the signal was not primarily hitting the stem cells or immune cells, as one might expect, but was instead binding strongly to the endothelial cells lining the blood vessels. In young mice, these blood vessel cells did not show this binding, but in middle-aged mice, a significant portion of them did. The researchers then created a special line of mice where they could turn off the RANK receptor specifically in the endothelial cells. In these mice, the signs of aging in the bone marrow were dramatically reduced. The blood vessels no longer triggered the inflammatory cascade, the stem cells remained healthy, and the bone marrow retained its ability to regenerate after injury. This confirmed that the endothelial cells were the primary source of the problem.
The next step was to understand how a signal in a blood vessel could cause damage to bone marrow stem cells. Through detailed genetic analysis, the researchers found that when the RANK receptor on endothelial cells was activated, it triggered the production of IL-1β. This inflammatory molecule then acted on the neighboring stem cells, which possess receptors to receive it. Once the stem cells received this signal, they began to show signs of severe stress, including damage to their DNA and a breakdown in their energy-producing mitochondria. This damage forced the cells into senescence, where they stopped dividing but continued to secrete inflammatory factors, further poisoning the local environment. The researchers demonstrated that if they blocked IL-1β directly, they could prevent this damage, keeping the stem cells young and functional even in older mice.
The study also looked beyond mice to see if these findings applied to humans. The researchers analyzed bone marrow samples from postmenopausal women who had been treated with a drug called denosumab, which is known to block the RANK signal. The analysis showed that women treated with this drug had significantly lower levels of inflammatory genes in their bone marrow compared to those who received a placebo. This suggests that the mechanism observed in mice is also active in humans and that blocking this pathway could potentially slow down the aging of the bone marrow in people.
These findings offer a new perspective on how aging begins in the bone marrow. Rather than being a random accumulation of damage, the process appears to be driven by a specific communication breakdown between blood vessels and the cells they support. The blood vessels, which are supposed to be the lifeline of the marrow, become a source of inflammation as they age, triggering a chain reaction that silences the body's regenerative potential. By identifying the RANK receptor on endothelial cells as the starting point, the study provides a clear target for intervention. It suggests that therapies designed to block this specific signal, or the inflammatory molecule it produces, could help maintain a youthful bone marrow environment, potentially delaying the onset of age-related blood disorders and improving the body's ability to heal. The work does not claim to stop aging entirely, but it reveals a critical lever that, if pulled, might allow the body to resist some of the most damaging effects of growing old.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.